Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.
Frontier Medicines Announces Series C Funding to Advance Development of Next Generation KRAS Blocker
Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.